Send to

Choose Destination
See comment in PubMed Commons below
Drugs. 2009 Jun 18;69(9):1141-52. doi: 10.2165/00003495-200969090-00001.

Ustekinumab: a new option in psoriasis therapy.

Author information

Department of Dermatology, University of Michigan Medical School, Ann Arbor, 48109-5314, USA.


Psoriasis is a chronic inflammatory disease that affects a significant portion of the population. Aside from the well known cutaneous and joint involvements, psoriasis is associated with a host of systemic ailments and risk factors. Thus, psoriasis can diminish a patient's quality and even length of life. Various systemic agents have been developed to control this condition, including the more recent introduction of biological agents. As the pathogenesis of psoriasis becomes better understood, a new class of biological drug is being studied and shows promise in long-term disease control for psoriasis patients, namely anti-interleukin-12/interleukin-23p40 monoclonal antibodies. The new biological agent, ustekinumab, has been shown to improve moderate to severe psoriasis in patients who cannot tolerate other treatment modalities with ease or in whom these modalities have failed. A favourable side effect profile has also been shown for this agent.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center